Boston Scientific's GAAP net income for 3 months of 2022 was $110 million, down 3.1 times from $341 million in the previous year. Revenues rose 10% to $3.026 billion from $2.752 billion a year earlier.

FDA has approved the use of Boston Scientific's STIMVIEW XT software. The technology allows you to build 3D models to monitor the brain when treating Parkinson's disease or essential tremor with electrodes. With STIMVIEW XT, electrode placement time is reduced by 56% to about 20 minutes.

Boston Scientific Corporation has completed its $1.75 billion acquisition of heart disease catheter developer Baylis Medical Company. The deal has allowed Boston Scientific to become one of the largest companies to provide a full suite of tools for left atrial auricle closure and atrial fibrillation ablation.

Boston Scientific's GAAP net income for 2021 was $1.041 billion, compared to a loss of $0.082 billion in the previous year. Revenue increased 26.8% to $8.177 billion from $6.448 billion a year earlier.